404 related articles for article (PubMed ID: 31544836)
1. The Ligands for Human IgG and Their Effector Functions.
de Taeye SW; Rispens T; Vidarsson G
Antibodies (Basel); 2019 Apr; 8(2):. PubMed ID: 31544836
[TBL] [Abstract][Full Text] [Related]
2. IgG subclasses and allotypes: from structure to effector functions.
Vidarsson G; Dekkers G; Rispens T
Front Immunol; 2014; 5():520. PubMed ID: 25368619
[TBL] [Abstract][Full Text] [Related]
3. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
4. Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA.
Cottignies-Calamarte A; Tudor D; Bomsel M
Front Immunol; 2023; 14():1037033. PubMed ID: 36817447
[TBL] [Abstract][Full Text] [Related]
5. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.
Schlothauer T; Herter S; Koller CF; Grau-Richards S; Steinhart V; Spick C; Kubbies M; Klein C; Umaña P; Mössner E
Protein Eng Des Sel; 2016 Oct; 29(10):457-466. PubMed ID: 27578889
[TBL] [Abstract][Full Text] [Related]
6. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
7. Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity.
Krapp S; Mimura Y; Jefferis R; Huber R; Sondermann P
J Mol Biol; 2003 Jan; 325(5):979-89. PubMed ID: 12527303
[TBL] [Abstract][Full Text] [Related]
8. The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms.
Mimura Y; Church S; Ghirlando R; Ashton PR; Dong S; Goodall M; Lund J; Jefferis R
Mol Immunol; 2000; 37(12-13):697-706. PubMed ID: 11275255
[TBL] [Abstract][Full Text] [Related]
9. The Influence of Human IgG Subclass and Allotype on Complement Activation.
Damelang T; de Taeye SW; Rentenaar R; Roya-Kouchaki K; de Boer E; Derksen NIL; van Kessel K; Lissenberg-Thunnissen S; Rooijakkers SHM; Jongerius I; Mebius MM; Schuurman J; Labrijn AF; Vidarsson G; Rispens T
J Immunol; 2023 Dec; 211(11):1725-1735. PubMed ID: 37843500
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
11. FcγR Binding and ADCC Activity of Human IgG Allotypes.
de Taeye SW; Bentlage AEH; Mebius MM; Meesters JI; Lissenberg-Thunnissen S; Falck D; Sénard T; Salehi N; Wuhrer M; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2020; 11():740. PubMed ID: 32435243
[TBL] [Abstract][Full Text] [Related]
12. Fc-Linked IgG
Zaytseva OO; Seeling M; Krištić J; Lauc G; Pezer M; Nimmerjahn F
Front Cell Dev Biol; 2020; 8():67. PubMed ID: 32195245
[TBL] [Abstract][Full Text] [Related]
13. Impact of structural modifications of IgG antibodies on effector functions.
Damelang T; Brinkhaus M; van Osch TLJ; Schuurman J; Labrijn AF; Rispens T; Vidarsson G
Front Immunol; 2023; 14():1304365. PubMed ID: 38259472
[TBL] [Abstract][Full Text] [Related]
14. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.
Borghi S; Bournazos S; Thulin NK; Li C; Gajewski A; Sherwood RW; Zhang S; Harris E; Jagannathan P; Wang LX; Ravetch JV; Wang TT
Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12943-12951. PubMed ID: 32461366
[TBL] [Abstract][Full Text] [Related]
15. Interaction sites on human IgG-Fc for FcgammaR: current models.
Jefferis R; Lund J
Immunol Lett; 2002 Jun; 82(1-2):57-65. PubMed ID: 12008035
[TBL] [Abstract][Full Text] [Related]
16. Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.
Dekkers G; Treffers L; Plomp R; Bentlage AEH; de Boer M; Koeleman CAM; Lissenberg-Thunnissen SN; Visser R; Brouwer M; Mok JY; Matlung H; van den Berg TK; van Esch WJE; Kuijpers TW; Wouters D; Rispens T; Wuhrer M; Vidarsson G
Front Immunol; 2017; 8():877. PubMed ID: 28824618
[TBL] [Abstract][Full Text] [Related]
17. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
18. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
19. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs.
Anthony RM; Ravetch JV
J Clin Immunol; 2010 May; 30 Suppl 1():S9-14. PubMed ID: 20480216
[TBL] [Abstract][Full Text] [Related]
20. Fc gamma receptors: glycobiology and therapeutic prospects.
Hayes JM; Wormald MR; Rudd PM; Davey GP
J Inflamm Res; 2016; 9():209-219. PubMed ID: 27895507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
